

# Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

<https://marketpublishers.com/r/M2894EFD6A5EN.html>

Date: March 2018

Pages: 66

Price: US\$ 3,500.00 (Single User License)

ID: M2894EFD6A5EN

## Abstracts

Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

### SUMMARY

According to the recently published report 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018'; Melanocortin Receptor 4 (MC4R) pipeline Target constitutes close to 10 molecules. Out of which approximately 8 molecules are developed by companies and remaining by the universities/institutes.

Melanocortin Receptor 4 (MC4R) - Melanocortin 4 receptor (MC4R) is a G protein-coupled receptor involved in the hypothalamic leptin-melanocortin signaling pathway. MC4R is encoded by the MC4R gene. Activation of the MC4R plays a key role in the maintenance of energy homeostasis and is associated with suppression of food intake.

The report 'Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018' outlays comprehensive information on the Melanocortin Receptor 4 (MC4R) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Phase I and Preclinical stages are 2, 1, 1 and 4 respectively. Similarly, the universities portfolio in Discovery stages comprises 2 molecules, respectively.

Report covers products from therapy areas Metabolic Disorders, Musculoskeletal Disorders, Women's Health, Central Nervous System, Genetic Disorders, Infectious Disease and Male Health which include indications Obesity, Type 2 Diabetes, Alphavirus Infections, Amyotrophic Lateral Sclerosis, Cachexia, Diabetes, Erectile Dysfunction, Female Hypoactive Sexual Desire Disorder, Female Sexual Dysfunction, Gouty Arthritis (Gout), Lipodystrophy, Metabolic Syndrome and Prader-Willi Syndrome (PWS).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Melanocortin Receptor 4 (MC4R)

The report reviews Melanocortin Receptor 4 (MC4R) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Melanocortin Receptor 4 (MC4R) targeted therapeutics and enlists all their major and minor projects

The report assesses Melanocortin Receptor 4 (MC4R) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Melanocortin Receptor 4 (MC4R) targeted therapeutics

## REASONS TO BUY

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Melanocortin Receptor 4 (MC4R)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Melanocortin Receptor 4 (MC4R) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Melanocortin Receptor 4 (MC4R) - Overview

Melanocortin Receptor 4 (MC4R) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Melanocortin Receptor 4 (MC4R) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Melanocortin Receptor 4 (MC4R) - Companies Involved in Therapeutics Development

AstraZeneca Plc

Mallinckrodt Plc

Palatin Technologies Inc

Melanocortin Receptor 4 (MC4R) - Drug Profiles

(liraglutide + setmelanotide) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AQB-565 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bremelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

corticotropin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PL-8905 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

setmelanotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Agonize MC4-R for Obesity - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize Melanocortin-4 Receptor for Cachexia - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Agonize Melanocortin 4 Receptor for Diabetes, Obesity, Female

Sexual Dysfunction and Erectile Dysfunction - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Melanocortin Receptor 4 (MC4R) - Dormant Products

Melanocortin Receptor 4 (MC4R) - Discontinued Products

Melanocortin Receptor 4 (MC4R) - Product Development Milestones

Featured News & Press Releases

Jan 30, 2018: First Patient Enrolled in Mallinckrodt Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Pulmonary Sarcoidosis

Jan 04, 2018: Rhythm Pharmaceuticals Announces Progress in Clinical Development of Setmelanotide for Treatment of Rare Genetic Disorders of Obesity

Dec 04, 2017: Mallinckrodt plc Presents Health Economic Data on Management of Infantile Spasms at American Epilepsy Society Annual Meeting

Oct 31, 2017: Rhythm Announces Preliminary Data from Phase 2 Study of Setmelanotide for Treatment of Bardet-Biedl Syndrome

Oct 26, 2017: Mallinckrodt Presents Multiple Sclerosis Relapse Data at 7th JointECTRIMS-ECTRIMS Meeting (MSParis2017)

Oct 09, 2017: Mallinckrodt Statement on October 7, 2017, CHEST Journal Article

Oct 09, 2017: Mallinckrodt Will Conduct Phase 4 Trial of H.P. Acthar Gel (Repository Corticotropin Injection) for Symptomatic Sarcoidosis

Sep 12, 2017: Open Letter to Mallinckrodt Employees, Customers and Patients  
Reinforcing Important Facts Related to H.P. Acthar Gel and Other Matters

Jul 31, 2017: Summary Review of Clinical and Economic Data on H.P. Acthar Gel  
Published in Advances in Therapy

Jul 25, 2017: Mallinckrodt Posts Data From Legacy H.P. Acthar Gel (Repository  
Corticotropin Injection) Pilot Study To [clinicaltrials.gov](https://clinicaltrials.gov)

Jun 27, 2017: Rhythm and Camurus Announce Positive Initial Data for Extended-  
Release Delivery of Setmelanotide for the Treatment of Rare Genetic Disorders of  
Obesity

Jun 26, 2017: MNK H.P. Acthar Gel DN Trial Results Alert

Jun 22, 2017: Mallinckrodt Statement on H.P. Acthar Gel Update

Jun 14, 2017: Mallinckrodt Enrolls First Patient in Phase 2B Trial of H.P. Acthar Gel  
(Repository Corticotropin Injection) for Amyotrophic Lateral Sclerosis

Jun 06, 2017: Mallinckrodt Updates Facts Refuting Short-Seller Claims

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H1 2018  
Number of Products under Development by Therapy Areas, H1 2018  
Number of Products under Development by Indication, H1 2018  
Number of Products under Development by Companies, H1 2018  
Products under Development by Companies, H1 2018  
Number of Products under Investigation by Universities/Institutes, H1 2018  
Products under Investigation by Universities/Institutes, H1 2018  
Number of Products by Stage and Mechanism of Actions, H1 2018  
Number of Products by Stage and Route of Administration, H1 2018  
Number of Products by Stage and Molecule Type, H1 2018  
Pipeline by AstraZeneca Plc, H1 2018  
Pipeline by Mallinckrodt Plc, H1 2018  
Pipeline by Palatin Technologies Inc, H1 2018  
Dormant Products, H1 2018  
Dormant Products, H1 2018 (Contd..1), H1 2018  
Discontinued Products, H1 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H1 2018

Number of Products under Development by Therapy Areas, H1 2018

Number of Products under Development by Top 10 Indications, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

### COMPANIES MENTIONED

AstraZeneca Plc

Mallinckrodt Plc

Palatin Technologies Inc



## I would like to order

Product name: Melanocortin Receptor 4 (MC4R) - Pipeline Review, H1 2018

Product link: <https://marketpublishers.com/r/M2894EFD6A5EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/M2894EFD6A5EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970